come was attributed to all organisms susceptible to pristinamycin. The dose and duration of pristinamycin therapy was at the discretion of the prescribing physician. There is no standardized testing method for pristinamycin susceptibility. Testing for in vitro susceptibility to quinupristin-dalfopristin by Vitek 2 was used as a proxy for pristinamycin susceptibility (7, 9) . Other antibiotic susceptibilities were determined according to standard NCCLS criteria. Coagulase-negative staphylococci (CNS) were grouped together and classified as either methicillin-sensitive CNS or methicillin-resistant CNS based on in vitro susceptibility testing.
Thirty-six patients were treated with pristinamycin for 46 microbiological isolates. Table 1 details the patient characteristics. Bone and joint infection was the most common indication, with 12 patients having osteomyelitis and 10 having prosthetic joint infections. Other indications included one prosthetic mitral valve endocarditis, one permanent pacemaker infection, two prosthetic vascular graft infections, four postoperative wound infections, two intravenous-line-related bacteremias, two intraabdominal infections, one urinary tract infection, and one epidural abscess. Tables 2 and 3 show details of individual patients and outcomes stratified to patient demographics.
Bacterial pathogens treated included 9 cases of methicillinsensitive Staphylococcus aureus, 4 of methicillin-resistant Staphylococcus aureus (MRSA), 4 of methicillin-sensitive CNS, 13 of methicillin-resistant CNS, 2 of Enterococcus faecalis, 2 of Enterococcus faecium, 9 of VRE (7 vancomycin-resistant Enterococcus faecium, 2 not speciated), and 2 of Corynebacte- on November 11, 2017 by guest http://aac.asm.org/ rium species. Fifteen patients had mixed infections; eight of these had more than one pathogen treated with pristinamycin. In all cases, in vitro sensitivity to quinupristin-dalfopristin was demonstrated prior to prescribing pristinamycin. Twenty-four patients were prescribed pristinamycin due to resistance to alternative oral antibiotics, nine patients were intolerant of first-line antibiotics, two patients had allergic reactions to the first-line antibiotics, and one patient failed to absorb rifampin due to short-gut syndrome. The median duration of treatment was 144 days (range, 3 to 876 days), and the median follow-up was 223 days (range, 35 to 876 days). The most common dosing regimen was 1 g every 8 h (q8h). Thirtytwo patients received other antibiotics before pristinamycin. Glycopeptide antibiotics were the most common of these.
Ten patients were cured of infection, 21 had suppressed infection, and 5 patients failed treatment. The median time of follow-up after the cessation of antibiotic treatment in cured patients was 95 days (26 to 566). All failures were due to antibiotic intolerance. Two patients died while on treatment. Neither of these was related to the infection or the treatment with pristinamycin.
Of the 11 patients reporting side effects, 6 experienced minor symptoms and continued treatment. Intolerant patients ceased therapy after a median of 31 days (2 to 42). Of these, three patients ceased treatment due to gastrointestinal side effects, one due to rash, and one due to neutropenia.
Of the 10 patients treated for prosthetic joint infections, 3 were cured, 6 were successfully suppressed, and 1 patient failed therapy due to drug intolerance. Seven patients retained their prostheses. Pathogens treated in prosthetic joint infections were MRSA in two patients, methicillin-sensitive CNS in two patients, five cases of methicillin-resistant CNS, one case of vancomycin-sensitive E. faecalis, one case of VRE, and one case due to Corynebacterium (note that two patients had dualpathogen infections).
Nine patients with VRE infections were treated with pristinamycin. Of these, seven had clinically suppressed infections. Two patients failed treatment due to drug intolerance. Of the four patients treated with sensitive enterococcal infections, three were cured and one had suppressed infection.
To date, only three studies describing the clinical utility of pristinamycin have been published in the English-language literature (3, 7, 9) . Two describe the use of pristinamycin for osteoarticular infections (7, 9) . One focuses on staphylococcal infections alone, with cure or suppression in 21 of 23 patients (7). This current study achieved cure or suppression in 21 of 22 patients with bone and joint infections. The second study reported cases of infection with several species of Gram-positive multidrug-resistant bacteria (9) . In that study, five of six patients treated for VRE failed treatment. This contrasts with the current study, in which nine patients had VRE infection, and all patients who tolerated pristinamycin (seven out of nine) had a successfully suppressed infection at the time of study completion. This study adds important information about the potential role of pristinamycin in treating VRE infection.
Given the prolonged therapy, the number of reported side effects was not surprising, but importantly the majority of these patients were able to continue treatment despite their symptoms. Patient numbers in this series are too small to comment on any factors associated with drug intolerance. 
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This study has a number of limitations, including its retrospective nature and the inherent lack of controls. A further limitation is the fact many patients were treated with other antibiotics. It therefore is impossible to establish the relative impact of these antibiotics on patient outcomes.
Our early pristinamycin experience has shown promising results, although larger series now are needed to explore issues such as drug tolerance and long-term outcomes. Pristinamycin appears to be a well-tolerated, effective oral alternative for treating difficult Gram-positive infections, including VRE and MRSA, in a number of difficult-to-treat or protected-site infections, including bone and joint infections and prosthetic device infections. 
